HPGC Renmintongtai Pharmaceutical EBIT

The latest EBIT for 600829.SS is $230M as of June 2026. That compares with $240M in the prior-year period — down 4.3% year over year. That is below the sector sector average of $2.6T. Investors often review this figure alongside HPGC Renmintongtai Pharmaceutical's historical trend and sector peers before judging valuation or financial health.

Over the past year, 600829.SS's EBIT moved from $240M to $230M — a 4.3% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in HPGC Renmintongtai Pharmaceutical's operating scale or balance-sheet position.

Against its sector companies, 600829.SS currently prints $230M for EBIT, while the sector average sits near $2.6T. That is roughly 100.0% below the sector mean. Large gaps often invite a closer look at HPGC Renmintongtai Pharmaceutical's growth, margins, and balance sheet.

A EBIT figure of $230M for 600829.SS is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The sector average is about $2.6T. Explore the charts below for those layers of context.

After noting 600829.SS's EBIT ($230M), review year-over-year change from $240M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.